Loading
Oncology societies already grade how much benefit each new drug gives. Payers should tie the maximum price they pay to that grade.
The ESMO Magnitude of Clinical Benefit Scale and ASCO Value Framework grade drugs by survival gain, quality of life and toxicity, but prices bear little relation to the grades; several analyses find no correlation between price and benefit. The proposal is for a coalition of public payers to publish a price corridor per benefit tier (for example a multiple of GDP per capita per life-year gained for grade 4-5 versus a much lower ceiling for grade 1-2) and to make the tier a binding input to negotiation, with prices revisited when confirmatory data change the grade.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, European Society for Medical Oncology (ESMO), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Incentives reward me-too drugs and marginal gains, Prices and value.